Basic Information

Common Name
CD33L3, HsT1361, SIGLEC-15
Catalog Number
Cell Type/Disease
Colon carcinoma
Mus musculus, C57BL/6
B-hSIGLEC15 MC38 cells have the capability to establish tumors in vivo and can be used for efficacy studies.


The mouse Siglec15 gene was replaced by human SIGLEC15 coding sequence in B-hSIGLEC15 MC38 cells. Human SIGLEC15 is highly expressed on the surface of B-hSIGLEC15 MC38 cells.

Targeting strategy

Gene targeting strategy for B-hSIGLEC15 MC38. The partial exon 3~3’UTR of mouse Siglec15 gene were knocked out and human SIGLEC15 CDS was insert into mouse Siglec15 exon 3 in B-hSIGLEC15 MC38.

Protein expression analysis

The SIGLEC15 expression analysis in B-hSIGLEC15 MC38 cells by flow cytometry. Single cells were collected from wild-type MC38 and B-hSIGLEC15 MC38 cells, and analyzed by flow cytometry with species-specific anti-SIGLEC15 antibody (in house). Human SIGLEC15 was exclusively detectable in B-hSIGLEC15 MC38 cells but not wild-type MC38 cells. The 3-D10 clone of B-hSIGLEC15 MC38 cells was used for in vivo experiments.

Tumor growth curve & Body weight changes

Subcutaneous homograft tumor growth of B-hSIGLEC15 MC38 cells. B-hSIGLEC15 MC38 cells (1×106) and wild-type MC38 cells (5×105 ) were subcutaneously implanted into the B-hSIGLEC15 mice (female, 8-week-old, n=6). Tumor volume and body weight were measured twice a week. (A) Average tumor volume ± SEM. (B)  Body weight (Mean± SEM). Volume was expressed in mm3 using the formula: V=0.5 X long diameter X short diameter2. As shown in panel A, B-hSIGLEC15 MC38 cells were able to establish tumors in vivo and can be used for efficacy studies.

Back to top